ACT-03 / Accure Therap - LARVOL DELTA

Incubation of depression: stress and the extracellular matrix (ECNP 2022) - "This indicates that balanced ECM levels coincide with intact hippocampal function, whereas periods of memory impairment co-occur with altered ECM levels.Next, we performed a pilot to counteract the acute ECM downregulation using an inhibitor of ECM breakdown (MMP inhibitor IPR-179/ACT-03; i.p.). Repeated injection was indeed able to prevent the initial stress-induced cognitive deficit. This suggests that ECM remodeling serves as a substrate in mediating stress-induced effects and that balanced ECM levels are vital for optimal memory processing."

Alzheimer's Disease • CNS Disorders • Depression • Mental Retardation • Mood Disorders • Psychiatry

The Gelatinase Inhibitor ACT-03 Reduces Gliosis in the Rapid Kindling Rat Model of Epilepsy, and Attenuates Inflammation and Loss of Barrier Integrity In Vitro. (PubMed, Biomedicines) - "In vitro, ACT-03 treatment attenuated stimulation-induced mRNA expression of several pro-inflammatory factors in human fetal astrocytes and brain endothelial cells, as well as a loss of barrier integrity in endothelial and astrocyte co-cultures. Since ACT-03 has disease-modifying effects in epilepsy models, possibly via limiting gliosis, inflammation, and barrier integrity loss, it is of interest to further evaluate its effects in a clinical trial."

Journal • Preclinical • CNS Disorders • Epilepsy • Immunology • Inflammation

New Spanish firm Accure Therapeutics launched (The Pharma Letter) - "...Accure Therapeutics, a new pharma R&D player in the central nervous system (CNS) field, announces its launch with a Series A round of funding totaling 7.6 million euros ($8.1 million). The funding round was led by Alta Life Sciences and supported by the Center for Technological and Industrial Development (CDTI)....The company will start work on three distinct new medicine programs focused on innovative targets....The initial assets, ACT-01 ready for testing in a clinical Phase II study and both ACT-02 and ACT-03 in preclinical experiments, have been sourced from two Spanish R&D companies (Bionure and Iproteos) and academic research centers with a strong scientific background in neurobiology."

Financing • New P2 trial • Preclinical • CNS Disorders